1341785-86-1 Usage
Uses
Used in Organic Synthesis:
3-Fluoro-4-(methoxymethyl)aniline serves as a key intermediate in organic synthesis, where it is employed as a building block for the construction of complex organic molecules. Its unique structure allows for versatile chemical reactions, facilitating the synthesis of a broad range of compounds.
Used in Pharmaceutical Manufacturing:
In the pharmaceutical industry, 3-Fluoro-4-(methoxymethyl)aniline is utilized as a precursor in the development of new drugs. Its specific functional groups enable targeted modifications that can enhance the pharmacological properties of the resulting drug molecules, such as potency, selectivity, and bioavailability.
Used in Chemical Research:
3-Fluoro-4-(methoxymethyl)aniline also plays a significant role in chemical research, where it is used to study the effects of structural modifications on the properties and reactivity of aniline derivatives. This knowledge can be applied to the design of new compounds with improved characteristics for various applications.
Used in Specialty Chemicals Production:
3-fluoro-4-(methoxymethyl)aniline finds application in the production of specialty chemicals, where its unique properties can be leveraged to create high-value products for niche markets. The versatility of 3-fluoro-4-(methoxymethyl)aniline makes it suitable for use in the development of advanced materials and fine chemicals.
Check Digit Verification of cas no
The CAS Registry Mumber 1341785-86-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,4,1,7,8 and 5 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1341785-86:
(9*1)+(8*3)+(7*4)+(6*1)+(5*7)+(4*8)+(3*5)+(2*8)+(1*6)=171
171 % 10 = 1
So 1341785-86-1 is a valid CAS Registry Number.
1341785-86-1Relevant articles and documents
COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
-
Page/Page column 436; 437; 438, (2019/02/13)
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.
NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF
-
Paragraph 1339-1341, (2018/02/28)
The problem to be solved by the present invention is to provide a novel compound having RET inhibitory activity. The present invention also provides a pharmaceutical preparation that is useful for the prevention and/or treatment of RET-related diseases, p
